DAXOR CORP - 10-Q Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2007. Daxor Corporation is a medical device manufacturer focused on the Blood Volume Analyzer (BVA) and related diagnostic kits (Volumex). The company also operates a cryobanking subsidiary (Scientific Medical Systems Corp.) providing blood and semen storage services. A significant portion of the company's financial profile is driven by a large investment portfolio, primarily consisting of electric utility stocks, which is used to offset operating losses.
Key Financial Metrics
For the Nine Months Ended September 30, 2007:
- Revenue: $1,400,747 (up 21.6% from $1,151,608 in 2006).
- Gross Profit: $883,937 (Gross Margin: 63.1%).
- Operating Loss: $(4,008,967) (slight improvement from $(4,041,109) in 2006).
- Net Income: $7,355,512 (compared to a Net Loss of $(832,454) in 2006).
- Diluted EPS: $1.60 (compared to $(0.18) in 2006).
- Investment Income: $11,535,156 (driven by $9.55M in realized gains on securities).
- Cash Flow: Net cash used in operating activities was $(2,352,515). Net cash provided by investing activities was $10,444,176. Net cash used in financing activities was $(10,915,892).
- Liquidity: Cash and cash equivalents decreased to $14,696 from $2,838,927 at year-end 2006. Total Current Assets: $80,747,289. Total Current Liabilities: $30,463,238.
- Debt: Loans payable decreased to $127,050. A new mortgage payable of $500,000 was incurred for a facility purchase in Tennessee.
Material Changes vs. Prior Period
- Revenue Growth: Driven by the sale of five Blood Volume Analyzers in the first nine months of 2007 (vs. two in 2006) and a 5% price increase on Volumex kits effective February 2007.
- Profitability Shift: The company swung from a net loss to a significant net income solely due to investment activities. Operating segments (Equipment and Cryobanking) continued to generate operating losses of $(4.0M).
- Investment Performance: Realized gains on securities surged to $9.55M (vs. $2.04M in 2006). Dividend income increased to $1.94M.
- Asset Base: Total assets increased to $82.8M, largely due to the investment portfolio valuation ($67.4M) and the acquisition of land and buildings in Oak Ridge, Tennessee ($784k).
- Cash Position: Despite net income, cash on hand dropped significantly due to financing activities (repayment of margin debt and bank loans) and operating cash outflows.
Outlook, Risks, and Management Commentary
- Regulatory Risk (CMS): The Centers for Medicare and Medicaid Services (CMS) announced a policy change effective January 1, 2008, which will no longer separately reimburse diagnostic radiopharmaceuticals (like Volumex) for outpatient services. Hospitals will absorb the cost. Management states the impact on 2008 revenue is currently unquantifiable but potentially material.
- SEC Investigation: The SEC has recommended action against the company and its CEO, Dr. Joseph Feldschuh, alleging violations of the Investment Company Act. The company maintains it is an operating company, not an investment company. The outcome and potential penalties remain uncertain.
- Concentration Risk: Seven hospital customers accounted for 47.42% of total sales in the first nine months of 2007. The company relies on a single FDA-approved manufacturer for Volumex syringes.
- Investment Strategy: The company continues to rely on its investment portfolio (85%+ in electric utilities) to fund operations. The portfolio holds a net unrealized gain of $42.5M. Management notes that without this income, the company would be in a precarious financial position due to persistent operating losses.
- Management Changes: A new five-year employment agreement was signed with the Vice President of Sales and Marketing, including a salary, bonus, stock options, and a mortgage loan benefit.
Investor Verification Checklist
- Investment Dependency: Verify the sustainability of the investment portfolio as the primary source of net income, given the continued operating losses in core medical device segments.
- CMS Policy Impact: Assess the potential revenue reduction from the January 2008 CMS reimbursement change for Volumex kits.
- SEC Enforcement: Monitor the status of the SEC investigation regarding the Investment Company Act classification and potential penalties.
- Liquidity Trends: Review the sharp decline in cash and cash equivalents ($2.8M to $14k) and the company's ability to fund operations without raising new capital.
- Customer Concentration: Evaluate the risk associated with nearly 50% of revenue coming from just seven hospital customers.